Current treatment status-Did not start treatment yet Posts on Medivizor
Navigation Menu

Current treatment status-Did not start treatment yet Posts on Medivizor

Evaluating short-course radiation therapy followed by chemotherapy for patients with rectal cancer.

Evaluating short-course radiation therapy followed by chemotherapy for patients with rectal cancer.

Posted by on Oct 9, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated short-course radiation therapy (RT) followed by chemotherapy as a non-surgical treatment of patients with rectal cancer (RC). The data showed that treatment with short-course RT and chemotherapy is safe and effective for these patients. Some background Colorectal cancer (CRC) is one of the most common types of...

Read More

Evaluating the effectiveness and safety of total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Evaluating the effectiveness and safety of total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Posted by on Jul 17, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy (CRT) for the treatment of patients with locally advanced rectal cancer (LARC). The data showed that TNT was associated with improved outcomes compared with standard CRT for these patients. Some background...

Read More

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell The study aimed to understand the long-term outcomes of focal laser therapy (FLT) in patients with prostate cancer. The study showed that this treatment has long-term survival without recurrence in certain patients.   Some background Surgical removal of the prostate gland is often recommended as a treatment for...

Read More

Is chemoradiotherapy before surgery needed for patients with stage II-III colorectal cancer?

Is chemoradiotherapy before surgery needed for patients with stage II-III colorectal cancer?

Posted by on Mar 14, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated whether chemoradiotherapy (CRT) before surgery improves the outcomes of patients with stage II-III colorectal cancer (CRC). The study found that CRT before surgery may not be needed in certain patients with low-risk disease. Some background CRC is the third most common cancer worldwide. The standard therapy for...

Read More

Dasatinib and blinatumomab for patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Dasatinib and blinatumomab for patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Posted by on Jan 4, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of dasatinib (Sprycel) and blinatumomab (Blincyto) as a first-line therapy in patients with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL).  This study concluded that this treatment combination led to better response and survival in these...

Read More

Evaluating long-term active surveillance for early-stage prostate cancer.

Evaluating long-term active surveillance for early-stage prostate cancer.

Posted by on Dec 28, 2020 in Prostate cancer | 0 comments

In a nutshell This study was carried out to assess the long-term outcomes of men diagnosed with prostate cancer (PC) undergoing active surveillance (AS) and factors that predicted the risk of their cancer spreading (metastasizing). The authors found that AS is a safe and viable option for men with low-risk and carefully-selected intermediate-risk...

Read More

The outcomes of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

The outcomes of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Posted by on Dec 18, 2020 in Lung cancer | 0 comments

In a nutshell The study compared outcomes of lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with ALK mutations (genetic abnormalities). The main finding was that patients receiving lorlatinib had longer progression-free survival (PFS) and a higher response in the...

Read More

Evaluating long-term outcomes of MRI-guided ultrasound ablation for prostate cancer.

Evaluating long-term outcomes of MRI-guided ultrasound ablation for prostate cancer.

Posted by on Dec 13, 2020 in Prostate cancer | 0 comments

In a nutshell This study was carried out to assess the long-term safety and effectiveness of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer. The authors found that TULSA was safe and effective, with preserved quality of life. Some background Prostate cancer is one...

Read More

Comparing chemotherapy-free treatments for patients with treatment naïve chronic lymphocytic leukemia

Comparing chemotherapy-free treatments for patients with treatment naïve chronic lymphocytic leukemia

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate three different chemotherapy-free treatment regimens for patients with chronic lymphocytic leukemia.  This study concluded that acalabrutinib (Calquence) plus obinutuzumab (Gazyva) improved survival without cancer worsening for these patients.   Some background Chemotherapy-free...

Read More

Evaluating the impact of surgical removal of tumors in non-Hodgkin lymphoma.

Evaluating the impact of surgical removal of tumors in non-Hodgkin lymphoma.

Posted by on Sep 29, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness of complete surgical removal of aggressive non-Hodgkin lymphoma (NHL). The authors found that in young patients with diffuse large B-cell lymphoma (DLBCL) may benefit from complete surgical removal of the tumor before immunochemotherapy (ICT).  Some background Lymphoma is a cancer that...

Read More